Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCG | P05129 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30743767 | 1.00 | PRKCG (0.31) | PRKCGPRKCAPRKCDFLT1AHR | |
| SCHEMBL29026587 | 0.76 | PRKCG (0.37) | PRKCGPRKCAPRKCDFLT1AHR | |
| SCHEMBL3881522 | 0.71 | PNMT (0.36) | — | |
| SCHEMBL22271440 | 0.71 | CD44 (0.41) | PRKCGPRKCAPRKCD | |
| SCHEMBL22271601 | 0.71 | GAA (0.50) | PRKCGPRKCAPRKCDFLT1AHR | |
| SCHEMBL24823064 | 0.71 | PRKCG (0.31) | PRKCGPRKCAPRKCD | |
| SCHEMBL1506627 | 0.71 | PRKCG (0.31) | PRKCGPRKCAPRKCD | |
| SCHEMBL30311025 | 0.71 | PRKCG (0.31) | PRKCGPRKCAPRKCD | |
| SCHEMBL2761891 | 0.69 | PRKCG (0.43) | PRKCGPRKCAPRKCD | |
| SCHEMBL9250961 | 0.69 | AHR (0.39) | FLT1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287053-A1 | COMPOUND, ENDOTHELIN-A RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | ALCHEMEDICINE, INC. (JP) | 2024-08-29 | — | — | US | disclosed |
| EP-4361146-A1 | COMPOUND, ENDOTHELIN-A RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | Alchemedicine, Inc. (JP) | 2024-05-01 | — | — | EP | disclosed |
| CN-117255791-A | Compounds, endothelin A receptor antagonists and pharmaceutical compositions | 亚克医药株式会社 | 2023-12-19 | — | — | CN | disclosed |
| WO-2022270487-A1 | COMPOUND, ENDOTHELIN-A RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | 株式会社アークメディスン | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287053-A1 | COMPOUND, ENDOTHELIN-A RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | EDNRA, EDNRB, ECE1 | PRKCG 1468/4885PRKCA 1393/4885PRKCD 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.